Predictive factors for vaccine failure to guide vaccination in allogeneic hematopoietic stem cell transplant recipients
Vaccination after hematopoietic stem cell transplantation (HSCT) is essential to protect high-risk patients against potentially lethal infections. Though multiple studies have evaluated vaccine specific responses, no comprehensive analysis of a complete vaccination schedule post-HSCT has been perfor...
Gespeichert in:
| Veröffentlicht in: | Bone marrow transplantation (Basingstoke) 2021-12, Vol.56 (12), p.2922-2928 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2928 |
|---|---|
| container_issue | 12 |
| container_start_page | 2922 |
| container_title | Bone marrow transplantation (Basingstoke) |
| container_volume | 56 |
| creator | Janssen, Michelle J. M. Bruns, Anke H. W. Verduyn Lunel, Frans M. Raijmakers, Reinier A. P. de Weijer, Roel J. Nanlohy, Nening M. Smits, Gaby P. van Baarle, Debbie Kuball, Jürgen |
| description | Vaccination after hematopoietic stem cell transplantation (HSCT) is essential to protect high-risk patients against potentially lethal infections. Though multiple studies have evaluated vaccine specific responses, no comprehensive analysis of a complete vaccination schedule post-HSCT has been performed and little is known about predictors for vaccine failure. In this context, allogeneic HSCT (alloHSCT) patients were included and vaccinated starting one year post-transplantation. Antibody responses were measured by Multiplex Immuno Assay for pneumococcal (PCV13), meningococcal C, diphtheria, pertussis, tetanus and
Haemophilus influenza
type b one month after the last vaccination and correlated to clinical and immunological parameters. Vaccine failure was defined as antibody response above vaccine-specific cut-off values for less than four out of six vaccines. Ninety-six patients were included of which 27.1% was found to have vaccine failure. Only 40.6% of all patients responded adequately to all six vaccines. In multivariate analysis, viral reactivation post-HSCT (OR 6.53;
P
= 0.03), B-cells |
| doi_str_mv | 10.1038/s41409-021-01437-0 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_2563421464</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A684564456</galeid><sourcerecordid>A684564456</sourcerecordid><originalsourceid>FETCH-LOGICAL-c434t-215f33ec488f8080639bbcaf9192946272c1b528e5fcea80cba4abcf2229fae83</originalsourceid><addsrcrecordid>eNp9kU-LFDEQxYMo7rj6BTxIQJC9tOZfZ9LHZdFVWNCDnkM6U5nJkk7aJL3itzftjK568BBCqn71eJWH0HNKXlPC1ZsiqCBDRxjtCBV825EHaEPFVnY9l_1DtCFMqo5zOZyhJ6XckkYJ0j9GZ1wIuu2l2qBvnzLsvK3-DrAztqZcsEsZ3xlrfVxrPiwZcE14v_gdnBqm-hSxj9iEkPYQwVt8gMnUNCcPtb1KhQlbCAHXbGKZg4kVZ7B-9hBreYoeORMKPDvd5-jLu7efr953Nx-vP1xd3nRWcFE7RnvHOVihlFNEEcmHcbTGDXRgg5Bsyywde6agdxaMInY0wozWMcYGZ0Dxc3Rx1J1z-rpAqXryZbVlIqSlaNZLLhgVUjT05T_obVpybO40k0QMijJG76m9CaB9dKntZ1dRfSmV6KVop1Gv_qAOYEI9lBSW9dvK3yA7gjanUjI4PWc_mfxdU6LXlPUxZd1S1j9T1qQNvTg5XcYJdr9HfsXaAH4ESmvFPeT7Vf4j-wMOKLJq</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2604981221</pqid></control><display><type>article</type><title>Predictive factors for vaccine failure to guide vaccination in allogeneic hematopoietic stem cell transplant recipients</title><source>MEDLINE</source><source>SpringerLink Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Janssen, Michelle J. M. ; Bruns, Anke H. W. ; Verduyn Lunel, Frans M. ; Raijmakers, Reinier A. P. ; de Weijer, Roel J. ; Nanlohy, Nening M. ; Smits, Gaby P. ; van Baarle, Debbie ; Kuball, Jürgen</creator><creatorcontrib>Janssen, Michelle J. M. ; Bruns, Anke H. W. ; Verduyn Lunel, Frans M. ; Raijmakers, Reinier A. P. ; de Weijer, Roel J. ; Nanlohy, Nening M. ; Smits, Gaby P. ; van Baarle, Debbie ; Kuball, Jürgen</creatorcontrib><description>Vaccination after hematopoietic stem cell transplantation (HSCT) is essential to protect high-risk patients against potentially lethal infections. Though multiple studies have evaluated vaccine specific responses, no comprehensive analysis of a complete vaccination schedule post-HSCT has been performed and little is known about predictors for vaccine failure. In this context, allogeneic HSCT (alloHSCT) patients were included and vaccinated starting one year post-transplantation. Antibody responses were measured by Multiplex Immuno Assay for pneumococcal (PCV13), meningococcal C, diphtheria, pertussis, tetanus and
Haemophilus influenza
type b one month after the last vaccination and correlated to clinical and immunological parameters. Vaccine failure was defined as antibody response above vaccine-specific cut-off values for less than four out of six vaccines. Ninety-six patients were included of which 27.1% was found to have vaccine failure. Only 40.6% of all patients responded adequately to all six vaccines. In multivariate analysis, viral reactivation post-HSCT (OR 6.53;
P
= 0.03), B-cells <135 per mm
3
(OR 7.24;
P
= 0.00) and NK-cells <170 per mm
3
(OR 11.06;
P
= 0.00) were identified as predictors for vaccine failure for vaccination at one year post-alloHSCT. Measurement of antibody responses and an individualized approach for revaccination guided by clinical status and immune reconstitution of B-cells and NK-cells may improve vaccine responses.</description><identifier>ISSN: 0268-3369</identifier><identifier>EISSN: 1476-5365</identifier><identifier>DOI: 10.1038/s41409-021-01437-0</identifier><identifier>PMID: 34417568</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>13/1 ; 631/250/255 ; 631/532/1542 ; 692/499 ; Antibodies ; Antibodies, Bacterial ; Antibody response ; Cell Biology ; Diphtheria ; Evaluation ; Failure ; Hematology ; Hematopoietic Stem Cell Transplantation ; Hematopoietic stem cells ; Humans ; Immune reconstitution ; Immune response ; Immunization ; Immunization Schedule ; Immunology ; Influenza ; Internal Medicine ; Lymphocytes B ; Medicine ; Medicine & Public Health ; Multivariate analysis ; Patient outcomes ; Patients ; Pertussis ; Physiological aspects ; Pneumococcal Vaccines ; Public Health ; Risk groups ; Stem cell transplantation ; Stem Cells ; Tetanus ; Transplantation ; Transplants & implants ; Vaccination ; Vaccines</subject><ispartof>Bone marrow transplantation (Basingstoke), 2021-12, Vol.56 (12), p.2922-2928</ispartof><rights>The Author(s), under exclusive licence to Springer Nature Limited 2021. corrected publication 2021</rights><rights>2021. The Author(s), under exclusive licence to Springer Nature Limited.</rights><rights>COPYRIGHT 2021 Nature Publishing Group</rights><rights>The Author(s), under exclusive licence to Springer Nature Limited 2021. corrected publication 2021.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c434t-215f33ec488f8080639bbcaf9192946272c1b528e5fcea80cba4abcf2229fae83</citedby><cites>FETCH-LOGICAL-c434t-215f33ec488f8080639bbcaf9192946272c1b528e5fcea80cba4abcf2229fae83</cites><orcidid>0000-0002-2710-1552 ; 0000-0002-3914-7806</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1038/s41409-021-01437-0$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1038/s41409-021-01437-0$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34417568$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Janssen, Michelle J. M.</creatorcontrib><creatorcontrib>Bruns, Anke H. W.</creatorcontrib><creatorcontrib>Verduyn Lunel, Frans M.</creatorcontrib><creatorcontrib>Raijmakers, Reinier A. P.</creatorcontrib><creatorcontrib>de Weijer, Roel J.</creatorcontrib><creatorcontrib>Nanlohy, Nening M.</creatorcontrib><creatorcontrib>Smits, Gaby P.</creatorcontrib><creatorcontrib>van Baarle, Debbie</creatorcontrib><creatorcontrib>Kuball, Jürgen</creatorcontrib><title>Predictive factors for vaccine failure to guide vaccination in allogeneic hematopoietic stem cell transplant recipients</title><title>Bone marrow transplantation (Basingstoke)</title><addtitle>Bone Marrow Transplant</addtitle><addtitle>Bone Marrow Transplant</addtitle><description>Vaccination after hematopoietic stem cell transplantation (HSCT) is essential to protect high-risk patients against potentially lethal infections. Though multiple studies have evaluated vaccine specific responses, no comprehensive analysis of a complete vaccination schedule post-HSCT has been performed and little is known about predictors for vaccine failure. In this context, allogeneic HSCT (alloHSCT) patients were included and vaccinated starting one year post-transplantation. Antibody responses were measured by Multiplex Immuno Assay for pneumococcal (PCV13), meningococcal C, diphtheria, pertussis, tetanus and
Haemophilus influenza
type b one month after the last vaccination and correlated to clinical and immunological parameters. Vaccine failure was defined as antibody response above vaccine-specific cut-off values for less than four out of six vaccines. Ninety-six patients were included of which 27.1% was found to have vaccine failure. Only 40.6% of all patients responded adequately to all six vaccines. In multivariate analysis, viral reactivation post-HSCT (OR 6.53;
P
= 0.03), B-cells <135 per mm
3
(OR 7.24;
P
= 0.00) and NK-cells <170 per mm
3
(OR 11.06;
P
= 0.00) were identified as predictors for vaccine failure for vaccination at one year post-alloHSCT. Measurement of antibody responses and an individualized approach for revaccination guided by clinical status and immune reconstitution of B-cells and NK-cells may improve vaccine responses.</description><subject>13/1</subject><subject>631/250/255</subject><subject>631/532/1542</subject><subject>692/499</subject><subject>Antibodies</subject><subject>Antibodies, Bacterial</subject><subject>Antibody response</subject><subject>Cell Biology</subject><subject>Diphtheria</subject><subject>Evaluation</subject><subject>Failure</subject><subject>Hematology</subject><subject>Hematopoietic Stem Cell Transplantation</subject><subject>Hematopoietic stem cells</subject><subject>Humans</subject><subject>Immune reconstitution</subject><subject>Immune response</subject><subject>Immunization</subject><subject>Immunization Schedule</subject><subject>Immunology</subject><subject>Influenza</subject><subject>Internal Medicine</subject><subject>Lymphocytes B</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Multivariate analysis</subject><subject>Patient outcomes</subject><subject>Patients</subject><subject>Pertussis</subject><subject>Physiological aspects</subject><subject>Pneumococcal Vaccines</subject><subject>Public Health</subject><subject>Risk groups</subject><subject>Stem cell transplantation</subject><subject>Stem Cells</subject><subject>Tetanus</subject><subject>Transplantation</subject><subject>Transplants & implants</subject><subject>Vaccination</subject><subject>Vaccines</subject><issn>0268-3369</issn><issn>1476-5365</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp9kU-LFDEQxYMo7rj6BTxIQJC9tOZfZ9LHZdFVWNCDnkM6U5nJkk7aJL3itzftjK568BBCqn71eJWH0HNKXlPC1ZsiqCBDRxjtCBV825EHaEPFVnY9l_1DtCFMqo5zOZyhJ6XckkYJ0j9GZ1wIuu2l2qBvnzLsvK3-DrAztqZcsEsZ3xlrfVxrPiwZcE14v_gdnBqm-hSxj9iEkPYQwVt8gMnUNCcPtb1KhQlbCAHXbGKZg4kVZ7B-9hBreYoeORMKPDvd5-jLu7efr953Nx-vP1xd3nRWcFE7RnvHOVihlFNEEcmHcbTGDXRgg5Bsyywde6agdxaMInY0wozWMcYGZ0Dxc3Rx1J1z-rpAqXryZbVlIqSlaNZLLhgVUjT05T_obVpybO40k0QMijJG76m9CaB9dKntZ1dRfSmV6KVop1Gv_qAOYEI9lBSW9dvK3yA7gjanUjI4PWc_mfxdU6LXlPUxZd1S1j9T1qQNvTg5XcYJdr9HfsXaAH4ESmvFPeT7Vf4j-wMOKLJq</recordid><startdate>20211201</startdate><enddate>20211201</enddate><creator>Janssen, Michelle J. M.</creator><creator>Bruns, Anke H. W.</creator><creator>Verduyn Lunel, Frans M.</creator><creator>Raijmakers, Reinier A. P.</creator><creator>de Weijer, Roel J.</creator><creator>Nanlohy, Nening M.</creator><creator>Smits, Gaby P.</creator><creator>van Baarle, Debbie</creator><creator>Kuball, Jürgen</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QO</scope><scope>7QP</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>P64</scope><scope>PHGZM</scope><scope>PHGZT</scope><scope>PJZUB</scope><scope>PKEHL</scope><scope>PPXIY</scope><scope>PQEST</scope><scope>PQGLB</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-2710-1552</orcidid><orcidid>https://orcid.org/0000-0002-3914-7806</orcidid></search><sort><creationdate>20211201</creationdate><title>Predictive factors for vaccine failure to guide vaccination in allogeneic hematopoietic stem cell transplant recipients</title><author>Janssen, Michelle J. M. ; Bruns, Anke H. W. ; Verduyn Lunel, Frans M. ; Raijmakers, Reinier A. P. ; de Weijer, Roel J. ; Nanlohy, Nening M. ; Smits, Gaby P. ; van Baarle, Debbie ; Kuball, Jürgen</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c434t-215f33ec488f8080639bbcaf9192946272c1b528e5fcea80cba4abcf2229fae83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>13/1</topic><topic>631/250/255</topic><topic>631/532/1542</topic><topic>692/499</topic><topic>Antibodies</topic><topic>Antibodies, Bacterial</topic><topic>Antibody response</topic><topic>Cell Biology</topic><topic>Diphtheria</topic><topic>Evaluation</topic><topic>Failure</topic><topic>Hematology</topic><topic>Hematopoietic Stem Cell Transplantation</topic><topic>Hematopoietic stem cells</topic><topic>Humans</topic><topic>Immune reconstitution</topic><topic>Immune response</topic><topic>Immunization</topic><topic>Immunization Schedule</topic><topic>Immunology</topic><topic>Influenza</topic><topic>Internal Medicine</topic><topic>Lymphocytes B</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Multivariate analysis</topic><topic>Patient outcomes</topic><topic>Patients</topic><topic>Pertussis</topic><topic>Physiological aspects</topic><topic>Pneumococcal Vaccines</topic><topic>Public Health</topic><topic>Risk groups</topic><topic>Stem cell transplantation</topic><topic>Stem Cells</topic><topic>Tetanus</topic><topic>Transplantation</topic><topic>Transplants & implants</topic><topic>Vaccination</topic><topic>Vaccines</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Janssen, Michelle J. M.</creatorcontrib><creatorcontrib>Bruns, Anke H. W.</creatorcontrib><creatorcontrib>Verduyn Lunel, Frans M.</creatorcontrib><creatorcontrib>Raijmakers, Reinier A. P.</creatorcontrib><creatorcontrib>de Weijer, Roel J.</creatorcontrib><creatorcontrib>Nanlohy, Nening M.</creatorcontrib><creatorcontrib>Smits, Gaby P.</creatorcontrib><creatorcontrib>van Baarle, Debbie</creatorcontrib><creatorcontrib>Kuball, Jürgen</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Biotechnology Research Abstracts</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest Central (New)</collection><collection>ProQuest One Academic (New)</collection><collection>ProQuest Health & Medical Research Collection</collection><collection>ProQuest One Academic Middle East (New)</collection><collection>ProQuest One Health & Nursing</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Applied & Life Sciences</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Bone marrow transplantation (Basingstoke)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Janssen, Michelle J. M.</au><au>Bruns, Anke H. W.</au><au>Verduyn Lunel, Frans M.</au><au>Raijmakers, Reinier A. P.</au><au>de Weijer, Roel J.</au><au>Nanlohy, Nening M.</au><au>Smits, Gaby P.</au><au>van Baarle, Debbie</au><au>Kuball, Jürgen</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Predictive factors for vaccine failure to guide vaccination in allogeneic hematopoietic stem cell transplant recipients</atitle><jtitle>Bone marrow transplantation (Basingstoke)</jtitle><stitle>Bone Marrow Transplant</stitle><addtitle>Bone Marrow Transplant</addtitle><date>2021-12-01</date><risdate>2021</risdate><volume>56</volume><issue>12</issue><spage>2922</spage><epage>2928</epage><pages>2922-2928</pages><issn>0268-3369</issn><eissn>1476-5365</eissn><abstract>Vaccination after hematopoietic stem cell transplantation (HSCT) is essential to protect high-risk patients against potentially lethal infections. Though multiple studies have evaluated vaccine specific responses, no comprehensive analysis of a complete vaccination schedule post-HSCT has been performed and little is known about predictors for vaccine failure. In this context, allogeneic HSCT (alloHSCT) patients were included and vaccinated starting one year post-transplantation. Antibody responses were measured by Multiplex Immuno Assay for pneumococcal (PCV13), meningococcal C, diphtheria, pertussis, tetanus and
Haemophilus influenza
type b one month after the last vaccination and correlated to clinical and immunological parameters. Vaccine failure was defined as antibody response above vaccine-specific cut-off values for less than four out of six vaccines. Ninety-six patients were included of which 27.1% was found to have vaccine failure. Only 40.6% of all patients responded adequately to all six vaccines. In multivariate analysis, viral reactivation post-HSCT (OR 6.53;
P
= 0.03), B-cells <135 per mm
3
(OR 7.24;
P
= 0.00) and NK-cells <170 per mm
3
(OR 11.06;
P
= 0.00) were identified as predictors for vaccine failure for vaccination at one year post-alloHSCT. Measurement of antibody responses and an individualized approach for revaccination guided by clinical status and immune reconstitution of B-cells and NK-cells may improve vaccine responses.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>34417568</pmid><doi>10.1038/s41409-021-01437-0</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0002-2710-1552</orcidid><orcidid>https://orcid.org/0000-0002-3914-7806</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0268-3369 |
| ispartof | Bone marrow transplantation (Basingstoke), 2021-12, Vol.56 (12), p.2922-2928 |
| issn | 0268-3369 1476-5365 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2563421464 |
| source | MEDLINE; SpringerLink Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | 13/1 631/250/255 631/532/1542 692/499 Antibodies Antibodies, Bacterial Antibody response Cell Biology Diphtheria Evaluation Failure Hematology Hematopoietic Stem Cell Transplantation Hematopoietic stem cells Humans Immune reconstitution Immune response Immunization Immunization Schedule Immunology Influenza Internal Medicine Lymphocytes B Medicine Medicine & Public Health Multivariate analysis Patient outcomes Patients Pertussis Physiological aspects Pneumococcal Vaccines Public Health Risk groups Stem cell transplantation Stem Cells Tetanus Transplantation Transplants & implants Vaccination Vaccines |
| title | Predictive factors for vaccine failure to guide vaccination in allogeneic hematopoietic stem cell transplant recipients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-20T15%3A15%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Predictive%20factors%20for%20vaccine%20failure%20to%20guide%20vaccination%20in%20allogeneic%20hematopoietic%20stem%20cell%20transplant%20recipients&rft.jtitle=Bone%20marrow%20transplantation%20(Basingstoke)&rft.au=Janssen,%20Michelle%20J.%20M.&rft.date=2021-12-01&rft.volume=56&rft.issue=12&rft.spage=2922&rft.epage=2928&rft.pages=2922-2928&rft.issn=0268-3369&rft.eissn=1476-5365&rft_id=info:doi/10.1038/s41409-021-01437-0&rft_dat=%3Cgale_proqu%3EA684564456%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2604981221&rft_id=info:pmid/34417568&rft_galeid=A684564456&rfr_iscdi=true |